EXECUTIVE SECRETARY REPORT – SEPTEMBER, 2017

- FINANCIAL REPORT

- TEMPORARY LICENSES

- STAFF ACTIVITIES
  - NAMSDL Meeting (D.C.) June 14-16 – Larry
  - Meeting with other health care boards & Governor’s staff re AB474 & SB59 – Dave, Larry, Brett, Paul
  - Pharmacy Law Symposium (Chicago) – July 19-20 – Larry
  - Law CE w RPD – August 28 & 30 – Dave Jones & Stacy
  - AG Subst Abuse Working Group – Larry
  - FBI CE – September 13 – Larry & Dave Jones
  - FDA 50 State Meeting on Compounding – D.C. – Larry & Dave

- REPORT TO BOARD
  - Letter to Board – Scott Ruedy
  - Veterinarian dispensing license update (Dave)
  - Pharmacy Practice Advisory Committee – Leo, Dave
  - Gabapentin scheduling or reporting in some states - Larry

- BOARD RELATED NEWS

- ACTIVITIES REPORT
<table>
<thead>
<tr>
<th>Regulation Number and Topic</th>
<th>Workshop Propose To Bd</th>
<th>30 Days To LCB W/Letter</th>
<th>LCB R0 Number Issued</th>
<th>LCB Return Date</th>
<th>30 Days Post Public Hearing</th>
<th>Public Hearing Meeting Date</th>
<th>To LCB Final W/Cov./Info</th>
<th>Secretary of State File Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>639.67** Compounding of Nasal Sprays</td>
<td>09/03/14 10/16/14</td>
<td>10/22/14</td>
<td>R140-14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.530 Schedule III - Hydrocodone</td>
<td>09/03/14</td>
<td>09/09/14</td>
<td>R137-14</td>
<td>10/22/14</td>
<td>10/23/14</td>
<td>12/03/14</td>
<td>12/12/14</td>
<td>12/22/14</td>
</tr>
<tr>
<td>453.520 Schedule II - Hydrocodone</td>
<td>09/03/14</td>
<td>09/09/14</td>
<td>R138-14</td>
<td>10/22/14</td>
<td>10/23/14</td>
<td>12/03/14</td>
<td>R138-14 included in R137-14</td>
<td>12/22/14</td>
</tr>
<tr>
<td>453.510 Schedule I – Adding certain controlled substances.</td>
<td>12/03/14</td>
<td>12/12/14</td>
<td>R142-14</td>
<td>07/31/15</td>
<td>08/26/15</td>
<td>10/15/15</td>
<td>10/28/15</td>
<td>12/21/15</td>
</tr>
<tr>
<td>639.050 Storage &amp; Destruction of Certain Drugs 639.498 Destruction of Controlled Substances</td>
<td>01/22/15</td>
<td>02/17/15</td>
<td>R002-15</td>
<td>07/31/15</td>
<td>08/26/15</td>
<td>10/15/15</td>
<td>10/28/15</td>
<td>12/21/15</td>
</tr>
<tr>
<td>639.6282 3PLs 639.6305 3PLs</td>
<td>01/22/15</td>
<td>02/17/15</td>
<td>R001-15</td>
<td>08/03/15</td>
<td>08/26/15</td>
<td>10/15/15</td>
<td>07/29/16</td>
<td></td>
</tr>
<tr>
<td>639.NEW Outsourcing Facilities</td>
<td>01/22/15</td>
<td>02/17/15</td>
<td>R003-15</td>
<td>08/18/15</td>
<td>08/26/15</td>
<td>10/15/15</td>
<td>10/28/15</td>
<td>12/21/15</td>
</tr>
<tr>
<td>453.510 Schedule I – Adding certain controlled substances.</td>
<td>04/16/15</td>
<td>04/29/15</td>
<td>Added to R142-14</td>
<td>07/31/15</td>
<td>08/26/15</td>
<td>10/15/15</td>
<td>10/28/15</td>
<td>12/21/15</td>
</tr>
<tr>
<td>453.540 Schedule IV - Suvorexant</td>
<td>04/16/15</td>
<td>04/29/15</td>
<td>R004-15</td>
<td>05/05/15</td>
<td>05/06/15</td>
<td>06/10/15</td>
<td>07/14/15</td>
<td>08/10/15</td>
</tr>
<tr>
<td>639.926 Transmission of CS Info</td>
<td>06/10/15</td>
<td>07/02/15</td>
<td>R047-15</td>
<td>09/17/15</td>
<td>10/28/15</td>
<td>12/02/15</td>
<td>01/27/16</td>
<td>04/04/16</td>
</tr>
<tr>
<td>453.510 Schedule I Cannabis, Cannabidiol &amp; Acetyl Fentanyl</td>
<td>09/02/15 04/13/17</td>
<td>09/08/15 05/03/17</td>
<td>R080-15</td>
<td>09/28/15 07/12/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.540 Lorcaserin – Schedule IV</td>
<td>09/02/15</td>
<td>09/08/15</td>
<td>R079-15</td>
<td>09/17/15</td>
<td>10/28/15</td>
<td>12/02/15</td>
<td>01/27/16</td>
<td>04/04/16</td>
</tr>
<tr>
<td>453.NEW Naloxone</td>
<td>09/02/15 10/15/15</td>
<td>10/22/15</td>
<td>R121-15</td>
<td>04/29/16</td>
<td>06/15/16</td>
<td>07/20/16</td>
<td>08/05/16</td>
<td>09/09/16</td>
</tr>
<tr>
<td>Regulation Number and Topic</td>
<td>Workshop Propose To Bd</td>
<td>30 Days To LCB W/Letter</td>
<td>LCB R0 Number Issued</td>
<td>LCB Return Date</td>
<td>30 Days Post Public Hearing</td>
<td>Public Hearing Meeting Date</td>
<td>To LCB Final W/Cov./Info</td>
<td>Secretary of State File Date</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>639.955 Penalty for failing to transmit information required by NAC 639.926</td>
<td>03/02/16</td>
<td>03/11/16</td>
<td>R036-16</td>
<td>04/08/16</td>
<td>04/27/16</td>
<td>06/01/16</td>
<td>06/16/16</td>
<td>06/28/16</td>
</tr>
<tr>
<td>639.921 Sharing information between systems.</td>
<td>03/02/16</td>
<td>03/11/16</td>
<td>R035-16</td>
<td>04/08/16</td>
<td>06/15/16</td>
<td>07/20/16</td>
<td>Denied 07/21/16</td>
<td></td>
</tr>
<tr>
<td>453.NEW Naloxone</td>
<td>01/13/16</td>
<td>04/07/16</td>
<td>R058-16</td>
<td>05/04/16</td>
<td>06/15/16</td>
<td>07/20/16</td>
<td>08/05/16</td>
<td>09/09/16</td>
</tr>
<tr>
<td>639.7102 Use of computer system for issuance and transmission of prescription</td>
<td>07/21/16</td>
<td>09/08/16</td>
<td>10/25/16</td>
<td>R154-16</td>
<td>07/05/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
</tr>
<tr>
<td>639.7105 Electronic transmission of prescription</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R151-16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAC 453.510 Schedule I add MAB-CHMINACA, AB-FUBINACA and ADB-PINACA</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R150-16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.540 Schedule IV add Eluxadoline</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R149-16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.550 Schedule V add Brivaracetam</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.NEW Naloxone recordkeeping</td>
<td>10/13/16</td>
<td>10/25/16</td>
<td>R-157-16</td>
<td>06/15/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.460 Partial Filling of Prescriptions</td>
<td>03/01/17</td>
<td>03/21/17</td>
<td>R-007-17</td>
<td>06/22/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.510 Schedule I adding certain controlled substances</td>
<td>04/13/17</td>
<td>05/03/17</td>
<td>R-011-17</td>
<td>06/29/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.530 Schedule III HCG in non-humans</td>
<td>06/01/17</td>
<td>06/07/17</td>
<td>R-013-17</td>
<td>06/14/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.440 DEA/ICD-10 Requirements</td>
<td>07/20/17</td>
<td>07/28/17</td>
<td>R-046-17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.926 Days Supply/Schedule V Reporting</td>
<td>07/20/17</td>
<td>07/28/17</td>
<td>R-045-17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TEMPORARY LICENSES
(Issued since last board meeting)

No temporary licenses have been issued since last meeting.
Placement of Substances into Schedule “A” – Model Act

**Highlights**

- Establishes a new controlled substance Schedule A for drugs or substances that: (1) have a chemical structure that is substantially similar to the chemical structure of any controlled substance; and (2) have an actual or predicted stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the effect on the central nervous system of any controlled substance.

- Provides for the temporary or permanent placement of a drug or substance into Schedule A if the drug or substance satisfies the criteria for inclusion and adding it into Schedule A will assist in preventing abuse or misuse of the drug or substance.

- Allows individual states to select the level of criminal penalties for the unlawful manufacture, distribution, or dispensing of Schedule A substances, but recommends no criminal penalty for simple possession of such substances.

- Requires Schedule A substances and products containing Schedule A substances to bear a label evidencing such at the time of manufacture, distribution, and dispensation.
PHARMACEUTICAL DIVERSION AND FRAUD

Presented by: Mike Salerno & Austin Broome, Detectives, Reno Police Department
Dave Jones, Compliance Coordinator, Nevada State Board of Pharmacy

"Law CE for pharmacists and pharmacy technicians through the State of Nevada Board of Pharmacy"

This course will address the growing issue of pharmaceutical diversion and abuse, and help the pharmacist and pharmacy technician understand his/her role in the prevention of this problem.

TOPICS INCLUDE:

- Highlights of the prescription drug misuse epidemic
- Case studies from local prescription fraud and diversion cases
- Recommendations to prevent prescription fraud and diversion
- Techniques to become a good witness and assist law enforcement in situations involving forged/ altered prescriptions and fraudulent call in prescriptions
- Discussion of tools available to prescribers and dispensers to combat prescription drug abuse
- Regulatory updates – including: PMP reporting on schedule V substances, new Naloxone distribution regulations, and changes to prescription requirements as a result of AB 474

WHEN: Monday, August 28th 6:00 – 8:00 p.m.
OR
Wednesday, August 30th 9:00 – 11:00 a.m.

WHERE: Regional Public Safety Training Center, Rm. 105
5190 Spectrum Blvd. Reno, NV 89512

COST: Free

Seating is limited – Call or email to reserve a space
*Choose ONE of the available class times*

Sponsored by:

Reno Police Department | Nevada Board of Pharmacy

To register, contact: Steve Wood | 775-789-5410 | sgwood@washoeCounty.us
Must RSVP before August 11th to attend the class
July 19, 2017

Nevada State Board of Pharmacy
431 W. Plumb Lane
Reno, NV 89059

RE: Case #16-072

Dear Board Members and Staff,

I would like to take the time to thank each Board Member and all of the staff that worked diligently to investigate and pursue the Disciplinary Actions against those involved in my daughter’s case. I had no knowledge or understanding of the Boards’ important role in protecting the safety of the citizens in the state of Nevada. My understanding of this process began in September 2016 when this incident occurred and I appreciate the professionalism and assistance I received from your staff throughout the process. They always were kind and understanding.

Although I asked for the revocation of licenses of those involved, I believe that Board came to a thoughtful, fair and equitable decision. In the end, my family just wanted to make sure that this would never happen again. The Board was mindful of the seriousness of what the pharmacist and technician did and gave me an opportunity to speak on behalf of my daughter.

Furthermore, we appreciate that the Pharmacy was directed to use this incident to educate their employees to prevent future incidents. The Board was clear that the most important responsibility of licensed professionals is to ensure patient safety.

Again, we are thankful for the courtesy, respect, kindness, sensitivity and urgency that all involved utilized to ensure that what happened was not in vain, and for that we will be forever grateful.

Sincerely,

Scott Ruedy,

On behalf of Sandra, Madison and David Ruedy

cc: Governor Sandoval
This report is prepared and presented to keep interested legislators and others abreast of the activities of the Nevada State Board of Pharmacy. Following is a summary of the July, 2017 Board meeting.

**Licensing Activity:**

- 17 licenses were granted for Out-of-State MDEG (Medical Devices, Equipment and Gases) companies and 3 granted for Nevada MDEG companies.
- 32 licenses were granted for Out-of-State pharmacies; pending receipt of a favorable inspection for all compounding pharmacies (2 applications were tabled).
- 28 licenses were granted for Out-of-State wholesalers, and 1 license was granted for a Nevada wholesaler.
- 3 licenses were granted for Nevada pharmacies and 1 application tabled.
- Pharmacist PY was granted licensure after satisfactorily addressing past controlled substances issues in another state in 2002.
- Pharmacist CK was denied licensure for forgery on an application document.
- Pharmacist KP was granted licensure pending a continued contract with PRN-PRN.
- PT JB was granted licensure pending a 5 year contract with PRN-PRN among other stipulations.

**Disciplinary Actions:**

- Pharmacist MP and her tech GK were disciplined for ignoring high dose alerts on a prescription for fentanyl patches for a child that resulted in dispensing a dose 10X stronger than intended. MP was suspended, with the suspension stayed; probation; public letter of reprimand and additional CE. Pharm. Tech GK will also receive a public letter of reprimand; additional CE; and ordered to attend the next 3 Las Vegas Board meetings. Pharmacy WG will pay admin fees & provide re-training to all Nevada employees.
- Pharmacist EK was suspended and ordered evaluation by PRN-PRN for diversion activities in California that she failed to report to the Nevada Board.
- Pharmacy WG had several employees working in the pharmacy not properly licensed. All managing pharmacists were disciplined as well as the employees themselves, with discipline including public letters of reprimand, fines, and additional CE.

**Other Activity:**

- The usual Board business reports were given, including recent and future speaking engagements; reports on national meetings; and collaboration with other state agencies.
- 2 pharmacies were approved to begin sterile compounding.
- Veterinary medication delivery models were discussed.
Workshop:

A. **Amendment of Nevada Administrative Code (NAC) 453.440 Prescriptions: Contents; additions and changes.** Changes to components of a written prescription. A written prescription must contain the registration number from the Drug Enforcement Administration (DEA) of the prescribing practitioner. Current Regulations allow the pharmacist to add the DEA number to the prescriptions. The new Law mandates that the practitioner must identify himself/herself by placing the DEA number on the prescription. The new Law also mandates that the prescription must contain the patient’s date of birth, days supply of the medication and the ICD-10 (International Classification of Diseases Tenth Revision) of the disease that is being treated.

B. **Amendment of Nevada Administrative Code (NAC) 639.926 Transmission of information regarding dispensing of controlled substances to certain persons.** Modification of Day Supply Reporting. Addition of ICD-10 Code (International Classification of Diseases Tenth Revision). Adding Schedule V drugs to the list of controlled substances that need to be reported to the Prescription Monitoring Program.